Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BAY-3563254 by Bayer for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
BAY-3563254 is under clinical development by Bayer and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
BAY-3018250 by Bayer for Pulmonary Embolism: Likelihood of Approval
BAY-3018250 is under clinical development by Bayer and currently in Phase II for Pulmonary Embolism. According to GlobalData, Phase II...
Vericiguat by Bayer for Vascular Dysfunction: Likelihood of Approval
Vericiguat is under clinical development by Bayer and currently in Phase II for Vascular Dysfunction. According to GlobalData, Phase II...
Vericiguat by Bayer for Metabolic Syndrome: Likelihood of Approval
Vericiguat is under clinical development by Bayer and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase II...
Elinzanetant by Bayer for Sleep Disorders: Likelihood of Approval
Elinzanetant is under clinical development by Bayer and currently in Phase II for Sleep Disorders. According to GlobalData, Phase II...
Regorafenib by Bayer for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
BAY-2927088 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2927088 is under clinical development by Bayer and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Elinzanetant by Bayer for Vasomotor Symptoms of Menopause (Hot Flashes): Likelihood of Approval
Elinzanetant is under clinical development by Bayer and currently in Pre-Registration for Vasomotor Symptoms of Menopause (Hot Flashes). According to...
Regorafenib by Bayer for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Regorafenib by Bayer for Esophageal Cancer: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Esophageal Cancer. According to GlobalData, Phase III...
Regorafenib by Bayer for Gastric Cancer: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...
BAY-3283142 by Bayer for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
BAY-3283142 is under clinical development by Bayer and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According...
BAY-2416964 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Bapotulimab by Bayer for Solid Tumor: Likelihood of Approval
Bapotulimab is under clinical development by Bayer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Bapotulimab by Bayer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Bapotulimab is under clinical development by Bayer and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Riociguat by Bayer for Sickle Cell Disease: Likelihood of Approval
Riociguat is under clinical development by Bayer and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bayer's Elinzanetant?
Elinzanetant is a small molecule commercialized by Bayer, with a leading Phase III program in Vasomotor Symptoms of Menopause (Hot...
Risk adjusted net present value: What is the current valuation of Bayer's Asundexian?
Asundexian is a small molecule commercialized by Bayer, with a leading Phase III program in Acute Ischemic Stroke. According to...
Vericiguat by Bayer for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Vericiguat is under clinical development by Bayer and currently in Phase II for Diastolic Heart Failure (HFpEF). According to GlobalData,...
Asundexian by Bayer for Myocardial Infarction: Likelihood of Approval
Asundexian is under clinical development by Bayer and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II...